HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study-Reference-Cited by-同舟云学术

HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study

Published:2019-08-12 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Halilovic Altuna^ORCID,Verweij Dagmar I.,Simons Annet,Stevens-Kroef Marian J. P. L.,Vermeulen Susan,Elsink Janet,Tops Bastiaan B. J.,Otte-Höller Irene,van der Laak Jeroen A. W. M.^ORCID,van de Water Carlijn,Boelens Oliver B. A.,Schlooz-Vries Margrethe S.,Dijkstra Jeroen R.,Nagtegaal Iris D.,Tol Jolien,van Cleef Patricia H. J.,Span Paul N.,Bult Peter

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-019-48212-2.pdf

Reference49 articles.

1. Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 353, 1659–1672 (2005).

2. Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353, 1673–1684 (2005).

3. Smith, I. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 369, 29–36 (2007).

4. Joensuu, H. et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol. 27, 5685–5692 (2009).

5. Chan, A. A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol. 18, 1152–1158 (2007).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype;Modern Pathology;2024-08

2. DNA content and clinicopathological features aid in distinguishing ameloblastic carcinoma from ameloblastoma;Journal of Oral Pathology & Medicine;2024-01

3. A review of HER2 overexpression and somatic mutations in cancers;Critical Reviews in Oncology/Hematology;2023-06

4. HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?;International Journal of Molecular Sciences;2023-05-04

5. Chinese expert consensus on the diagnosis and treatment of HER2 ‐altered non–small cell lung cancer;Thoracic Cancer;2022-11-28